Relevant bibliographies by topics / Vaccines

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccines'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccines"

1

Ricke, Darrell O. "Etiology model for many vaccination adverse reactions, including SARS-CoV-2 spike vaccines." AIMS Allergy and Immunology 6, no. 4 (2022): 200–215. http://dx.doi.org/10.3934/allergy.2022015.

Full text
Abstract:
<abstract><sec> <title>Objective</title> <p>Vaccinated individuals (vaccinees) experience no adverse events, mild adverse events, multiple adverse events, or serious adverse events post vaccination. Many of these vaccine adverse events occur with different vaccines with different occurrence frequencies. Many of these adverse events are generally considered as associated with immune responses to the active vaccine components (antigens) and/or to possibly one or more of the vaccine excipients. Most of these vaccine adverse events are self-limiting and resolve within days. The number of vaccine adverse reactions is higher for SARS-CoV-2 spike vaccines than all other vaccines. Can data analysis of vaccine adverse reactions responses provide etiology insights for high reactogenicity vaccines?</p> </sec><sec> <title>Methods</title> <p>The Vaccine Adverse Event Reporting System (VAERS) database was data mined for all vaccine adverse events data by vaccine, age, gender, dose, and day of onset post vaccination. Results for vaccines with the highest number of adverse events were compared.</p> </sec><sec> <title>Results</title> <p>For vaccines and adverse events with the highest numbers of reports, the day of onset approximates a power of two decay pattern for the first three days. The consistency of this pattern for multiple unrelated vaccines narrows possible etiology mechanisms. Many of these adverse event symptoms overlap symptoms associated with elevated histamine levels. Herein, innate immune responses and specifically elevated histamine levels are proposed to be causative for the majority of these adverse events. This hypothesis is based on a model of innate immune responses releasing a surge of inflammatory molecules, including histamine; this surge is hypothesized to exceed the normal histamine tolerance level for vaccinees causing reactogenicity adverse events. Further, these symptoms resolve as histamine levels fall below the vaccinee's tolerance threshold. This model can be evaluated by the detection of elevated histamine levels in vaccinees corresponding to timing of symptoms onset. If confirmed, a direct consequence of this model predicts that specific antihistamine treatments, mast cell stabilizers, and possibly diamine oxidase enzyme may reduce the incidence or severity of adverse events experienced by vaccinees post vaccinations for most or all high reactogenicity vaccines including coronavirus disease 2019 (COVID-19) spike vaccines.</p> </sec><sec> <title>Conclusions</title> <p>The reported onset occurrences of the majority of reported adverse events are consistent with the likely etiology of innate immune responses to vaccinations for vaccines with higher reactogenicity levels. Herein, the hypothesis is proposed that the majority of these adverse events result from a histamine surge that temporarily exceeds the vaccinee's tolerance level.</p> </sec></abstract>
APA, Harvard, Vancouver, ISO, and other styles
2

Okanlawon, A. A., S. A. Ameen, R. A. Kadir, H. M. Ambali, Y. A. Baba, O. M. Azeez, and A. A. Owoade. "In vitro assessment of the potency of some Newcastle disease vaccine brands in Ibadan, Nigeria." African Journal of Clinical and Experimental Microbiology 21, no. 4 (August 25, 2020): 328–32. http://dx.doi.org/10.4314/ajcem.v21i4.9.

Full text
Abstract:
Background: Newcastle disease (ND) is a very common and economically important disease of poultry. There is no drug for treatment of the disease during an outbreak in poultry flocks, and prevention by vaccination is one of the recommended control measures. However, post vaccination outbreaks have been observed on many occasions in chicken flocks and one of the causes has been attributed to possible failure of vaccine to confer immunity. This study was designed to evaluate the potency of ND vaccines available in Ibadan, Nigeria. Methodology: Haemagglutination (HA) technique and elution phenomenon were employed to evaluate the potency of ND vaccines randomly selected in Ibadan. A total of 45 vaccines comprising 9 brands and 5 different strains were selected for potency test. The vaccine brands included ‘Vireo 116’ (n=10), ‘ABIC’ (n=5), ‘Biovac’(n=9), ‘Nobilis’(n=3), ‘NVRI’(n=12), ‘R2B’ (n=2), ‘BAL-ND’ (n=2), ‘Forte dodge’(n=1) and ‘Jovac’ (n=1), while the vaccine strains in the brands included Lasota, B1, Clone, Komarov, Hitcher, and an unknown strain. Results: Thirty-five of the 45 (77.8%) ND vaccines tested had more than 4 HA titer (>64) and were therefore regarded as potent. All the 15 (100%) ND Lasota vaccine strain, 7 out of 10 (70%) ND Komarov strain, 4 out of 5 (80%) ND clone and 5 out of 8 (62.5%) ND B1 strains were potent. None of the ND brand ‘R2B’ vaccine as well as Hitchner strain from ‘Nobilis’ brand was potent, but all 5, 2, 1 and 1 vaccines tested from brands ‘ABIC’, ‘BAL-ND’, ‘Fort dodge’ and ‘Jovac’ respectively were potent. Similarly, 9 of 10, 6 of 9, 2 of 3 and 9 of 12 vaccine strains tested from brands ‘Vireo 116’, ‘Biovac’, ‘Nobilis’ and ‘NVRI’ were respectively potent Conclusion: The occurrence of ND vaccines that are not potent in this study may be contributing to post vaccination failure. It is advisable to subject vaccines to potency test before use. Key words: in vitro, assessment, potency, Newcastle disease, vaccine brands, vaccine strains French Title; Évaluation in vitro de la puissance de certaines marques de vaccins contre la maladie de Newcastle à Ibadan, Nigéria Contexte: La maladie de Newcastle (ND) est une maladie très courante et économiquement importante des volailles. Il n'existe aucun médicament pour le traitement de la maladie lors d'une épidémie dans des troupeaux de volailles, et la prévention par vaccination est l'une des mesures de contrôle recommandées. Cependant, des flambées post-vaccination ont été observées à de nombreuses reprises dans des troupeaux de poulets et l'une des causes a été attribuée à un éventuel échec du vaccin à conférer l'immunité. Cette étude a été conçue pour évaluer la puissance des vaccins contre la MN disponibles à Ibadan, au Nigéria. Méthodologie: La technique d'hémagglutination (HA) et le phénomène d'élution ont été utilisés pour évaluer la puissance des vaccins contre la MN sélectionnés au hasard à Ibadan. Un total de 45 vaccins comprenant 9 marques et 5 souches différentes ont été sélectionnés pour le test d'activité. Les marques de vaccins comprenaient 'Vireo 116' (n=10), 'ABIC' (n=5), 'Biovac' (n=9), 'Nobilis' (n=3), 'NVRI' (n=12), 'R2B' (n=2), 'BAL-ND' (n=2), 'Forte dodge' (n=1) et 'Jovac' (n=1), tandis que les souches vaccinales des marques comprenaient Lasota, B1, Clone, Komarov, Hitcher et une souche inconnue. Résultats: Trente-cinq des 45 vaccins contre la MN testés (77,8%) avaient plus de 4 titres en HA (>64) et étaient donc considérés comme puissants. Toutes les 15 (100%) souches de vaccin ND Lasota, 7 souches sur 10 (70%) ND Komarov, 4 sur 5 (80%) clones ND et 5 sur 8 (62,5%) souches ND B1 étaient puissantes. Aucun des vaccins ’R2B’ de marque ND ni la souche Hitchner de la marque ’Nobilis’ n'étaient puissants, mais tous les vaccins 5, 2, 1 et 1 testés des marques ‘ABIC’, ‘BAL-ND’, ‘Fort dodge’ et ‘Jovac’ respectivement était puissant. De même, 9 des 10, 6 des 9, 2 des 3 et 9 des 12 souches vaccinales testées des marques ’Vireo 116’, ‘Biovac’, ‘Nobilis’ et ‘NVRI’ étaient respectivement puissantes Conclusion: La présence de vaccins contre la MN qui ne sont pas puissants dans cette étude peut contribuer à l'échec post-vaccinal. Il est conseillé de soumettre les vaccins à un test de puissance avant utilisation. Mots-clés: in vitro, évaluation, puissance, maladie de Newcastle, marques de vaccin, souches vaccinales
APA, Harvard, Vancouver, ISO, and other styles
3

Broderick, Michael P., Sandra Romero-Steiner, Gowrisankar Rajam, Scott E. Johnson, Andrea Milton, Ellie Kim, Lisa J. Choi, et al. "Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone." Clinical and Vaccine Immunology 23, no. 8 (June 8, 2016): 672–80. http://dx.doi.org/10.1128/cvi.00267-16.

Full text
Abstract:
ABSTRACTImmunological responses to vaccination can differ depending on whether the vaccine is given alone or with other vaccines. This study was a retrospective evaluation of the immunogenicity of a tetravalent meningococcal conjugate vaccine for serogroups A, C, W, and Y (MenACWY) administered alone (n= 41) or concomitantly with other vaccines (n= 279) to U.S. military personnel (mean age, 21.6 years) entering the military between 2006 and 2008. Concomitant vaccines included tetanus/diphtheria (Td), inactivated polio vaccine (IPV), hepatitis vaccines, and various influenza vaccines, among others; two vaccine groups excluded Tdap and IPV. Immune responses were evaluated in baseline and postvaccination sera forNeisseria meningitidisserogroups C and Y 1 to 12 months (mean, 4.96 months) following vaccination. Functional antibodies were measured by using a serum bactericidal antibody assay with rabbit complement (rSBA) and by measurement of serogroup-specific immunoglobulin G (IgG) antibodies. The percentage of vaccinees reaching threshold levels (IgG concentration in serum, ≥2 μg/ml; rSBA titer, ≥8) corresponding to an immunologic response was higher postvaccination than at baseline (P< 0.001). Administration of MenACWY along with other vaccines was associated with higher geometric means of IgG concentrations and rSBA titers than those measured 4.60 months after a single dose of MenACWY. In addition, higher percentages of vaccinees reached the immunological threshold (range of odds ratios [ORs], 1.5 to 21.7) and more of them seroconverted (OR range, 1.8 to 4.8) when MenACWY was administered with any other vaccine than when administered alone. Additional prospective randomized clinical trials are needed to confirm the observed differences among groups in the immune response to MenACWY when given concomitantly with other vaccines to U.S. military personnel.
APA, Harvard, Vancouver, ISO, and other styles
4

Trombetta, Claudia Maria, Otfried Kistner, Emanuele Montomoli, Simonetta Viviani, and Serena Marchi. "Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines." Vaccines 10, no. 5 (May 1, 2022): 714. http://dx.doi.org/10.3390/vaccines10050714.

Full text
Abstract:
Influenza is a vaccine preventable disease and vaccination remains the most effective method of controlling the morbidity and mortality of seasonal influenza, especially with respect to risk groups. To date, three types of influenza vaccines have been licensed: inactivated, live-attenuated, and recombinant haemagglutinin vaccines. Effectiveness studies allow an assessment of the positive effects of influenza vaccines in the field. The effectiveness of current influenza is suboptimal, being estimated as 40% to 60% when the vaccines strains are antigenically well-matched with the circulating viruses. This review focuses on influenza viruses and vaccines and the role of vaccine effectiveness studies for evaluating the benefits of influenza vaccines. Overall, influenza vaccines are effective against morbidity and mortality in all age and risk groups, especially in young children and older adults. However, the effectiveness is dependent on several factors such as the age of vaccinees, the match between the strain included in the vaccine composition and the circulating virus, egg-adaptations occurring during the production process, and the subject’s history of previous vaccination.
APA, Harvard, Vancouver, ISO, and other styles
5

Yagovkin, E. A., G. G. Onishchenko, A. Yu Popova, E. B. Ezhlova, A. A. Melnikova, M. Yu Soloviev, E. V. Kovalev, et al. "Condition and Prospects of Development of Vaccines for Specific Prevention of Enterovirus (Nonpolio) Infection." Epidemiology and Vaccine Prevention 15, no. 4 (August 20, 2016): 74–82. http://dx.doi.org/10.31631/2073-3046-2016-15-4-74-82.

Full text
Abstract:
This review summarizes the material on the development of vaccines against (nonpolio) enterovirus infection in Russia and abroad. Described the developed vaccine types, their characteristics and the results of clinical and epidemiological trials, created in China inactivated vaccines. I’is considered the possibility of creating a mucosal vaccines and vaccinal prevention strategies.
APA, Harvard, Vancouver, ISO, and other styles
6

Le, Ting, Chao Sun, Jitao Chang, Guijie Zhang, and Xin Yin. "mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases." Viruses 14, no. 2 (February 15, 2022): 401. http://dx.doi.org/10.3390/v14020401.

Full text
Abstract:
In the prevention and treatment of infectious diseases, mRNA vaccines hold great promise because of their low risk of insertional mutagenesis, high potency, accelerated development cycles, and potential for low-cost manufacture. In past years, several mRNA vaccines have entered clinical trials and have shown promise for offering solutions to combat emerging and re-emerging infectious diseases such as rabies, Zika, and influenza. Recently, the successful application of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine’s potential in infectious disease prevention, especially in the veterinary field. In this review, we describe our current understanding of the mRNA vaccines and the technologies used for mRNA vaccine development. We also provide an overview of mRNA vaccines developed for animal infectious diseases and discuss directions and challenges for the future applications of this promising vaccine platform in the veterinary field.
APA, Harvard, Vancouver, ISO, and other styles
7

Cheng, Liqin, Yan Wang, and Juan Du. "Human Papillomavirus Vaccines: An Updated Review." Vaccines 8, no. 3 (July 16, 2020): 391. http://dx.doi.org/10.3390/vaccines8030391.

Full text
Abstract:
Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated information about current HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination and current clinical trials are also discussed. Currently, more efforts should be put into increasing the vaccine’s coverage, especially in low- and middle-income countries. Provision of education on HPV and vaccination is one of the most important methods to achieve this. Vaccines that target HPV types not included in current vaccines are the next stage in vaccine development. In the future, all HPV-related cancers, such as head and neck cancer, and anal cancer, should be tracked and evaluated, especially in countries that have introduced pan-gender vaccination programs. Therapeutic vaccines, in combination with other cancer treatments, should continue to be investigated.
APA, Harvard, Vancouver, ISO, and other styles
8

Choi, Wongyeong, and Eunha Shim. "Vaccine Effects on Susceptibility and Symptomatology Can Change the Optimal Allocation of COVID-19 Vaccines: South Korea as an Example." Journal of Clinical Medicine 10, no. 13 (June 25, 2021): 2813. http://dx.doi.org/10.3390/jcm10132813.

Full text
Abstract:
The approved coronavirus disease (COVID-19) vaccines reduce the risk of disease by 70–95%; however, their efficacy in preventing COVID-19 is unclear. Moreover, the limited vaccine supply raises questions on how they can be used effectively. To examine the optimal allocation of COVID-19 vaccines in South Korea, we constructed an age-structured mathematical model, calibrated using country-specific demographic and epidemiological data. The optimal control problem was formulated with the aim of finding time-dependent age-specific optimal vaccination strategies to minimize costs related to COVID-19 infections and vaccination, considering a limited vaccine supply and various vaccine effects on susceptibility and symptomatology. Our results suggest that “susceptibility-reducing” vaccines should be relatively evenly distributed among all age groups, resulting in more than 40% of eligible age groups being vaccinated. In contrast, “symptom-reducing” vaccines should be administered mainly to individuals aged 20–29 and ≥60 years. Thus, our study suggests that the vaccine profile should determine the optimal vaccination strategy. Our findings highlight the importance of understanding vaccine’s effects on susceptibility and symptomatology for effective public health interventions.
APA, Harvard, Vancouver, ISO, and other styles
9

Neri, Margherita, Simon Brassel, and Lotte Steuten. "OP256 Recognising The Broader Value Of Vaccines In Health Technology Assessment: Worth A Shot?" International Journal of Technology Assessment in Health Care 37, S1 (December 2021): 9–10. http://dx.doi.org/10.1017/s0266462321000878.

Full text
Abstract:
IntroductionThe COVID-19 pandemic shows that the impact of effective vaccines extends well beyond vaccinated individuals and healthcare systems. Yet, these externalities are not typically considered in health technology assessments (HTA) which may underestimate vaccines’ broader value. We explored to what extent future vaccines relevant to England might exhibit such broader value.MethodsWe compared the ten value elements of an existing vaccine evaluation framework to the value elements considered in England according to the Joint Committee on Vaccine and Immunisation (JCVI) and the National Institute for Health and Care Excellence's (NICE) guidelines. Using literature and expert opinion we then explored, for a selection of ten vaccines with an expected UK-launch within five years, on which value elements each vaccine might potentially show added value.ResultsUp to five of ten value elements are unlikely to be considered by JCVI or NICE, including patient and carer productivity, enablement value, impact on antimicrobial resistance and transmission value. Of vaccines studied, 100 percent will potentially generate value on at least one broader value element that is currently ignored; 60 percent to 80 percent may increase vaccinee/patient or carer productivity respectively.ConclusionsThere is a substantial gap between value generation and value recognition of vaccines in HTA in England. This might lead to undervaluation and underutilization of vaccines, leaving societies more vulnerable than needed when faced with infectious diseases.
APA, Harvard, Vancouver, ISO, and other styles
10

Malik, Sumira, Shristi Kishore, Sagnik Nag, Archna Dhasmana, Subham Preetam, Oishi Mitra, Darwin A. León-Figueroa, et al. "Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges." Vaccines 11, no. 2 (January 26, 2023): 268. http://dx.doi.org/10.3390/vaccines11020268.

Full text
Abstract:
The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan, Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre-designed vaccines for use in the battle against EVD, which has affirmed the urgent need for the development of a systematic protocol to produce Ebola vaccines prior to an outbreak. There are several vaccines available being developed by preclinical trials and human-based clinical trials. The group of vaccines includes virus-like particle-based vaccines, DNA-based vaccines, whole virus recombinant vaccines, incompetent replication originated vaccines, and competent replication vaccines. The limitations and challenges faced in the development of Ebola vaccines are the selection of immunogenic, rapid-responsive, cross-protective immunity-based vaccinations with assurances of prolonged protection. Another issue for the manufacturing and distribution of vaccines involves post authorization, licensing, and surveillance to ensure a vaccine’s efficacy towards combating the Ebola outbreak. The current review focuses on the development process, the current perspective on the development of an Ebola vaccine, and future challenges for combatting future emerging Ebola infectious disease.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccines"

1

Farfan, Arribas Diego Jose. "DNA Vaccines Against HIV-1: Augmenting Immunogenicity of gp120." Link to electronic thesis, 2002. http://www.wpi.edu/Pubs/ETD/Available/etd-0107102-160706/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Parker, Christopher S. "Effect of a codon optimized DNA prime on induction of anti-influenza protective antibodies." Worcester, Mass. : Worcester Polytechnic Institute, 2007. http://www.wpi.edu/Pubs/ETD/Available/etd-040907-100839/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Satti, Iman. "Immunogenicity of anti-leishmaniasis vaccines in man /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-779-7/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rainczuk, Adam 1976. "Evaluation of DNA vaccine targeting strategies and expression library immunisation against lethal erythrocytic stage Malaria." Monash University, Dept. of Biochemistry and Molecular Biology, 2003. http://arrow.monash.edu.au/hdl/1959.1/5685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Grubb, Kimberley L. "A genomic approach to the identification of novel malaria vaccine antigens /." Thesis, McGill University, 2005. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=98715.

Full text
Abstract:
As the number of drug-resistant malaria parasites continues to grow, pressure is increasing to find an effective, cross-protective, multi-valent malaria vaccine (32). Expression library immunisation is an un-biased screening technique that leads to the identification of novel, protective antigens that can be administered as components of a multivalent DNA vaccine (9, 50, 75, 86, 92). Here, a P. c. adami DS expression library has been evaluated as a malaria vaccine in mice, and several subpools of cross-protective plasmids have been identified. Upon vaccination with these plasmid subpools, mice demonstrate significantly lower mean cumulative parasitemia values than control vaccinated mice, when challenged with avirulent heterologous P. c. adami DK parasites. These cross-protective responses correlate with the induction of opsonizing antibodies against infected red blood cells and the production of IFN-gamma by T-cells. The determination of P. c. adami antigens capable of inducing strain-transcending immunity implies the identification of orthologues in the P. falciparum genome that may be applied as components of a human malaria vaccine.
APA, Harvard, Vancouver, ISO, and other styles
6

Atcheson, Erwan. "Prospects for enhancing malaria vaccine efficacy by combining pre-erythrocytic antigens." Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:6506c003-7065-4d48-b049-f5e9136443d5.

Full text
Abstract:
Malaria causes almost half a million deaths each year. Existing interventions will almost certainly not be enough to tackle this enormous public health problem on their own. An effective vaccine is urgently needed. The leading malaria vaccine, RTS,S, confers suboptimal protective efficacy, and in addition targets only Plasmodium falciparum and not the other major species of human malaria, P. vivax. This thesis investigates the potential of combining pre-erythrocytic malaria vaccines as a means of enhancing protective efficacy. A novel mathematical model was developed which expresses probability of protection as a function of vaccine-induced humoural and cellular responses. The model predicts that combining partially effective vaccines should result in more than additive improvements in protective efficacy. This was supported by an experiment combining Rv21, a P. vivax circumsporozoite virus-like particle, with viral vectored P. vivax TRAP, the two leading pre-erythrocytic malaria vaccine antigens; this combination raised protective efficacy from 50% and 0%, respectively, to 100% sterile protection. It was also found that antigenic interference, a reduction in anti-CSP titres when Rv21 and PvTRAP are combined, occurred only in the presence of Matrix M adjuvant, and not when using alum, AddaVax or no adjuvant. With a view to creating a single-component multi-antigen vaccine, which would be more cost-effective than a multi-component vaccine, experiments were carried out to establish the virus-like particle Qβ as a platform capable of eliciting protective immunity via the display of short peptides derived from the CSP repeat region of both P. vivax and P. falciparum. For the first time, a tetramer peptide derived from the CSP repeat region of P. vivax VK210, AGDR, was shown capable of eliciting protective immunity alone. Finally, five novel linear B-cell epitopes were discovered, one from P. falciparum CSP, three from P. vivax TRAP and one from TRSP, each capable of conferring partial protection on mice. These epitopes were identified using novel screening methods, using sera from whole-protein vaccinated mice or by exploiting conservation within invasion protein sequences. Two of the protective epitopes, (NANP)6 and (ADGN long) were combined and found to enhance protective efficacy as predicted by the mathematical model. Thus this thesis lays the groundwork for the development of a single-component multi-epitope malaria vaccine with enhanced protective efficacy.
APA, Harvard, Vancouver, ISO, and other styles
7

Hutchings, Claire L. "Combination vaccines." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.437038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Singh, Gagandeep. "RNA Viral Prophylaxis: Problems and Potential Solutions." Diss., North Dakota State University, 2019. https://hdl.handle.net/10365/29458.

Full text
Abstract:
Over 80% of the newly emerging infectious diseases are caused by RNA viruses. Major global problems associated with the development of vaccines against the RNA virus are their high genetic and antigenic diversity. Hence, effective control of epidemics with newly emerging RNA viruses require improved vaccines which are either specific to the new strain or broadly effective even when new viral strains emerge. The main focus of this dissertation is to develop epidemic vaccines using these two approaches. Using a newly emerged swine enteric virus called porcine epidemic diarrhea virus (PEDV) as a model, our first goal was to develop a quick and easy method for rapid response vaccines with potential applicability to a range of RNA viruses. We hypothesized that the methods which can disrupt genomic RNA without impacting the structural integrity of the virus would result in attenuated vaccine with minimum replication in the host while inducing immune responses. As hypothesized, developed rapid response PEDV vaccine induced complete protection against the virulent challenge virus, while vaccine viral shedding was not detected in vaccinated pigs. To address the second problem of rapid viral evolution leading to vaccines becoming obsolete, we used swine influenza virus (SIV) as a model to develop and test a universal vaccine composed of peptides encoding conserved antigenic epitopes which are present in most influenza A viruses. Importantly, a novel amphiphilic invertible polymer (AIP) was used to address the well-recognized problem of poor antigenicity of peptides. We hypothesized that peptides encoding conserved epitopes when conjugated with an AIP will induce strong immune responses and protect against challenge virus. While the conserved epitopes were previously tested by others in mice, we were the first to test a combination of these epitopes in pigs. Pigs vaccinated with the peptide polymer vaccine mounted strong antibody responses against the epitopes indicating that the delivery system was effective. However, protection against replication of the challenge virus was delayed. In summary, the methods developed and tested in this body of work significantly contribute to the area of emergency response management in infectious disease outbreaks.
United States Department of Agriculture, National Institute of Food and Agriculture (USDA-NIFA)
North Dakota State Agricultural Products Utilization Committee (ND APUC)
North Dakota State Board of Agricultural Research (ND SABRE)
APA, Harvard, Vancouver, ISO, and other styles
9

Khan, Tila. "Tailored influenza virus vaccines for both the young and old: Vaccine Efficacy of Whole Inactivated Vaccines bearing Immunomodulatory Adjuvants or Multimeric peptides." Diss., Virginia Tech, 2012. http://hdl.handle.net/10919/77130.

Full text
Abstract:
Influenza epidemics and pandemics remain a significant burden to world health and economy. Low efficacy of current inactivated influenza vaccines in the elderly and immunocompromized and the inability to protect against antigenically drifted or shifted strains of influenza virus are the two major problems in influenza vaccine research. To overcome these hurdles, we have utilized an in vitro cell culture vaccine platform, which results in whole inactivated influenza vaccine (WIV) bearing bioactive membrane-anchored immunomodulatory proteins such as cytokines on the virion surface, collectively known as CYT-IVACs (Cytokine bearing-Inactivated Vaccine). In addition, we tested whether a multimeric M2e peptide presented on WIV can serve to enhance immunogenicity and augment protective efficacy of whole virus vaccines. Our panel of cytokines includes IL-2, IL-4, IL-12, IL-23, and Flt3L as well as the multimeric M2e peptide, all fused to the membrane anchoring regions of influenza virus hemagglutinin protein and constitutively expressed in virus permissive MDCK cell line. Subsequent infection with influenza virus results in incorporation of fusion constructs directly into budding progeny virions that are harvested, purified and inactivated to generate distinct CYT-IVAC formulations. Following validation of immunomodulator incorporation, vaccines were tested for in vivo efficacy in either "young adult" or "aged" female Balb/c mice. Our results demonstrate that our CYT-IVAC~IL-12/HA and CYT-IVAC~IL-23/HA serve as potent mucosal adjuvants in young adult mice elicited significantly high levels of mucosal IgA antibodies and afford superior protection against lethal virus challenge. Our Flt3L/HA formulation was the most effective stimulator of systemic anti-viral antibody levels. In "aged" mice a single dose formulation of IL-12 bearing CYTIVAC was superior at affording protection against lethal homotypic virus challenge. Finally, administration of multimeric M2e molecule co-presented on WIV elicited prolonged antibody responses in "young adult mice" and provided cross-protection from challenge with the heterologous influenza A pandemic strain 2009 H1N1. In conclusion, the CYT-IVAC approach represents a novel tailored advancement to current WIV approaches that has the potential to elicit both potent mucosal and systemic immune responses in young and old.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
10

Dannetun, Eva. "Reasons for non-vaccination /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-739-1/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccines"

1

1925-, Brown Fred, and Cold Spring Harbor Laboratory, eds. Vaccines 90: Modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gregoriadis, Gregory, Anthony C. Allison, and George Poste, eds. Vaccines. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gregoriadis, Gregory, Brenda McCormack, and Anthony C. Allison, eds. Vaccines. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4613-0357-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Domachowske, Joseph, and Manika Suryadevara, eds. Vaccines. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-58414-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Perlmann, Peter, and Hans Wigzell, eds. Vaccines. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59955-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Misch, Kelly, Cathleen Dalton, and William D. Martineau. Vaccines. Cleveland, Ohio: Freedonia Group, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sylvia, Engdahl, ed. Vaccines. Detroit: Greenhaven Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1932-, Plotkin Stanley A., and Orenstein Walter A, eds. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Co., 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Goldstein, Natalie. Vaccines. New York, NY: Chelsea House, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Laboratory, Cold Spring Harbor. Vaccines. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccines"

1

Wu, Chung-Yi, and Chi-Huey Wong. "Vaccines Vaccine." In Glycoscience: Biology and Medicine, 1529–36. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54841-6_198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jain, Ananya, and Shilpa Sharma. "Nanotechnology in COVID-19 Vaccines." In Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022), 14–26. Dordrecht: Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_3.

Full text
Abstract:
AbstractNanotechnology has been proposed in vaccine development as carriers and adjuvants time and again but received limited recognition before the development of vaccines for the COVID-19 pandemic. Nanotechnology has played a pivotal role in the triumph of the vaccines for the current pandemic caused by the SARS-CoV-2 virus. The first vaccine got approved within a year of the earliest reported case of the novel coronavirus. Presently, more than 35 vaccines are approved in at least one country, 10 out of which are sanctioned for emergency use by the WHO. The key categories include peptide vaccine, mRNA vaccine, inactivated & viral vector vaccines. Nanotechnology is a crucial component in the success of mRNA vaccines. Nanoparticles not only allow targeted drug delivery but also boost the pharmacokinetic profile and the immune response against the therapeutic. A few nanoparticles have received approval for use as adjuvants (MF59), and countless others (virosomes, PGLA) are under development for many vaccines for infectious diseases, for instance, Influenza, Hepatitis B, Human Papillomavirus, Malaria, Tuberculosis, etc. In this article, we will review the vaccines available against SARS-CoV-2 with a focus on the nanotechnology utilized in their development.
APA, Harvard, Vancouver, ISO, and other styles
3

Smith, G. L. "Recombinant vaccinia virus vaccines." In Recent Developments in Prophylactic Immunization, 313–33. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spithill, Terry W., Hayley Toet, Vignesh Rathinasamy, Gemma Zerna, Jaclyn Swan, Timothy Cameron, Peter M. Smooker, David M. Piedrafita, Robert Dempster, and Travis Beddoe. "Vaccines for Fasciola: new thinking for an old problem." In Fasciolosis, 379–422. 2nd ed. Wallingford: CABI, 2021. http://dx.doi.org/10.1079/9781789246162.0012.

Full text
Abstract:
Abstract This book chapter discusses the progression of fascioliasis vaccine research, as well as commercial considerations in fascioliasis vaccines development and characteristics of commercial vaccines.
APA, Harvard, Vancouver, ISO, and other styles
5

Knight, Stella C. "Dendritic Cells in the Induction of Immunity." In Vaccines, 1–6. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Oosterlaken, Tom A. M., Theo Harmsen, Cornelis A. Kraaijeveld, and Harm Snippe. "Efficient Anti-Idiotypic Immunization with Homologous, Virus Neutralizing Monoclonal Antibodies Conjugated with KLH and Combined with Quil A." In Vaccines, 93–98. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bartoloni, A., M. G. Pizza, A. Covacci, D. Nucci, L. Nencioni, and R. Rappuoli. "Protein Conformation Affects the Efficacy of Pertussis Vaccines." In Vaccines, 99–105. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Epstein, M. A. "Vaccination Against Epstein-Barr Virus." In Vaccines, 107–12. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hsu, K.-H., M. Lubeck, S. Mizutani, R. Natuk, M. Chengalvala, P. Chanda, R. Bhat, et al. "Adenovirus Vectored Vaccines." In Vaccines, 113–19. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Makela, P. Helena, Helena Kayhty, Aino K. Takala, Heikki Peltola, and Juhani Eskola. "Vaccines Against Bacterial Infections of Children." In Vaccines, 121–35. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3848-6_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccines"

1

Kumar, Vishnu, Vijay Srinivasan, and Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19." In ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.

Full text
Abstract:
Abstract Biopharmaceutical community is devising modern techniques to boost the development, production, and distribution of COVID-19 vaccines in large scale with tremendous speed. This has shifted the focus towards smart manufacturing of vaccines through vaccine platforms. Vaccine platforms have great potential to rapidly generate new vaccines and can overcome the challenges of the traditional vaccine manufacturing approach without compromising on safety and efficacy. This preliminary study compares the traditional and modern vaccine manufacturing techniques, reviews COVID-19 vaccine manufacturing scenarios, and presents a framework to critique on the smartness of the novel platform-based COVID-19 vaccine development and manufacturing.
APA, Harvard, Vancouver, ISO, and other styles
2

Tarabrin, R. E., and E. S. Pyatigorec. "BIOETHICAL ISSUES OF VACCINOMICS." In I International Congress “The Latest Achievements of Medicine, Healthcare, and Health-Saving Technologies”. Kemerovo State University, 2023. http://dx.doi.org/10.21603/-i-ic-130.

Full text
Abstract:
Vaccinomics, as one of the areas of personalized medicine, can increase the effectiveness of vaccines, including in epidemics. Nevertheless, it is accompanied by a cluster of bioethical issues. The article explores possible bioethical difficulties associated with the development of personalized vaccines: the matching of the research subject and the person receiving the vaccine; the problem of confidential genetic data; equitable distribution of medical resources.
APA, Harvard, Vancouver, ISO, and other styles
3

Zughaier, Susu. "High Vaccine Coverage is Crucial for Preventing the Spread of Infectious Diseases During Mass Gathering." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0138.

Full text
Abstract:
Background: Vaccines are the most cost-effective intervention in public health as they prevent the spread of highly contagious infectious diseases. Because of vaccine implementation and high coverage, Measles was eradicated in 2000, however the recent reappearance of measles in the United States, Europe and globally is alarming. The resurgence of Measles, Diphtheria and Mumps is due to a reduction in vaccine coverage and herd immunity. Vaccine hesitant parents, antivaxxers, and fake news on vaccines are driving the surge in those infectious diseases. The World Health Organization issued the Global Vaccine and Immunization Action Plan to reiterate the importance of vaccine implementation and coverage for several vaccine-preventable infectious diseases in the world. Qatar is preparing for the upcoming FIFA World Cup 2022 therefore maintaining high vaccine coverage, which is critical in preventing infectious diseases spreading during such mass gathering. Methods: Literature search for vaccine coverage rates, resurgence of vaccine preventable infectious diseases and risks of mass gatherings. Results: Seventeen infectious diseases are currently vaccine-preventable. The cost-effectiveness of vaccine is documented as it is estimated for each dollar spent on vaccines, 10 dollars are saved in disease treatment. A drop in vaccine coverage rates to under 90% lead to the resurgence of measles. Vaccine coverage rate in Qatar is currently at 95% which is one of the highest in the world. Qatar must maintain this high coverage rate to prevent any measles outbreaks during mass gatherings. The planned World Cup event will take place from November 21 till December 18 2022, which is the peak for seasonal influenza. In preparedness for this major event, Qatar should encourage residents and visitors to be vaccinated not just against measles and seasonal influenza, but also hepatitis and meningitis. Conclusion: Maintaining 95% vaccine coverage rate is critical for preventing the resurgence of vaccine-preventable infectious diseases during the World Cup mass gathering in Qatar.
APA, Harvard, Vancouver, ISO, and other styles
4

Bularca, Maria Cristina, Claudiu Coman, Luiza Mesesan Schmitz, Doina Draguinea, and Radu Tudorica. "THE ROLE OF ONLINE MEDIA CHANNELS IN PORTRAYING THE EFFECTS OF THE COVID-19 VACCINE." In 9th SWS International Scientific Conferences on SOCIAL SCIENCES - ISCSS 2022. SGEM WORLD SCIENCE, 2022. http://dx.doi.org/10.35603/sws.iscss.2022/s10.100.

Full text
Abstract:
During the COVID -19 pandemic, among other institutions, mass media has played an essential role in disseminating information about the evolution of the pandemic, but also in shaping peoples� opinion about the COVID - 19 vaccine. The purpose of our paper was to identify the way online media channels portrayed the positive and negative effects of the COVID � 19 vaccines in order to raise awareness regarding the importance of analyzing the subject from several perspectives. We considered such an analysis to be both necessary and relevant, because often, exposure to mass � media can determine people to develop certain beliefs and to act in specific ways. We were interested in identifying which types of vaccines were presented in a more positive manner, and in identifying similarities and differences between the approaches of Romanian and foreign online media channels. Content analysis was used as a method, while having as a research instrument a content analysis grid. The sample of the research includes 5 official websites of Romanian media channels and 5 official websites of foreign media channels. The analysis period was: August 2020 - October 2020. The results of our research revealed that online media presented the COVID -19 vaccines both from a positive and negative perspective, the vaccines discussed most being the Russian vaccines, AstraZeneca and the Chinese vaccines. The context in which the vaccines was described most were represented by: effectiveness of vaccines and side effects. Considering the theoretical and practical implications, from a theoretical point of view, the paper contributes to the literature on the effects and influence of mass � media. From a practical point of view, the paper can be used as a frame of reference for further studying the influence of the messages sent through online media about the COVID � 19 vaccines on the public.
APA, Harvard, Vancouver, ISO, and other styles
5

Krishnakumar, D., and K. S. Jaganathan. "Development of nasal HPV vaccine formulations." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.

Full text
Abstract:
Cervical cancer is the second most cancer in women worldwide with over 500000 new cases and 275000 deaths being registered every year. With nearly 73000 women dying every year, India now tops the world in cervical cancer deaths. India represents 26.4% of all women dying of cervical cancer globally. Cervical cancer estimated to be responsible for about 5% of human cancers worldwide. Currently available vaccines may not provide complete protection against all HPV types as the protection is primarily type specific. Furthermore, the available vaccines are delivered via intramuscular route and require three doses and require cold chain supply which increases the cost of vaccine. Therefore a single dose vaccine delivered via non-invasive route (nasal) that protects against multiple HPV types would be a cost effective and better alternative to the currently available HPV vaccines. The main objective of this study was to prepare HPV antigen loaded poly (lactic-co-glycolic acid) (PLGA) and Tri Methyl Chitosan (TMC) coated PLGA microparticles and compare their efficacy as nasal vaccine. The developed formulations were characterized for size, zeta potential, entrapment efficiency, mucin adsorption ability, in vitro and in vivo studies. PLGA microparticles demonstrated negative zeta potential whereas PLGA-TMC microparticles showed higher positive zeta potential. The protein loading efficiency was found as above 80%. Results indicated that PLGA-TMC microparticles demonstrated substantially higher mucin adsorption when compared to PLGA microparticles. HPV antigen encapsulated in PLGA-TMC particles elicited a significantly higher secretory (IgA) immune response compared to that encapsulated in PLGA particles. Present study demonstrates that PLGA-TMC microparticles with specific size range can be a better carrier adjuvant for nasal subunit vaccines. Surface modified PLGA microparticles proved great potential as a nasal delivery system for HPV infections where systemic and mucosal responses are necessary particularly in conditions after viral pathogens invade the host through the mucosal surface.
APA, Harvard, Vancouver, ISO, and other styles
6

Camargo, Luana Cristina, Joao Paulo Figueiro Longo, Karen Letycia Rodrigues de Paiva, Marina Mesquita Simões, Thais Bergmann, and Victor Carlos Mello da Silva. "Immunotherapy vaccines for triple-negative breast cancer and its influence on the tumor microenvironment." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1024.

Full text
Abstract:
Objective: Cancer is still a complex and debilitating disease even though advances in treatment have occurred. Triplenegative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis and occurs more frequently in young women. Due to its metastatic features and unique tumor microenvironment, TNBC treatment is limited. In this study, we evaluated how three chemotherapy drugs could be used to produce vaccines with cells under immunogenic cell death. Methodology: For that, 4T1-luc2 cells were treated with cisplatin (100 μM), mitoxantrone (MTX) (15 μM), and doxorubicin (DOX) (50 μM) for 24 h. Then, the treated cells were injected subcutaneously in tumor-bearing Balb/c female mice, after the tumor challenge. The treatment occurred three times, once a week. During and after the treatment, primary tumor and metastatic progression were followed using the chemiluminescence technique. After 5 weeks of the tumor challenge, mice were euthanized and organs (liver, tumor, lungs, and spleen) were collected for analysis. Additionally, the spleens were processed for flow cytometry for regulatory T lymphocyte and myeloid-derived suppressor cells analysis. Results: Cisplatin and MTX vaccines slowed the primary and metastatic tumor growth as well as the decreased tumor, liver, and spleen weight, while the DOX vaccine slowed the metastatic tumor progression in the lungs but did not alter tumor and other organs’ weight. Moreover, cisplatin and MTX vaccine increased the ratio of lymphocytes in the spleen but not the DOX vaccine. All comparison was done regarding the tumor-bearing mice treated with PBS. Conclusion: Taken together, both MTX and cisplatin vaccines treated primary and secondary tumors probably by the increase of lymphocyte recruitment, and the cisplatin vaccine also has an influence on the tumor microenvironment. Finally, the therapeutical vaccine might be an interesting approach as a treatment for TNBC due to its positive effect on metastasis and tumor microenvironment, especially with cisplatin.
APA, Harvard, Vancouver, ISO, and other styles
7

"What factors are related to practicing COVID-19 vaccine by population at Ghawr Al-Safi, Jordan." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/yrrz1540.

Full text
Abstract:
Background: COVID-19 vaccines have been offered in Jordan since early march 2021, to all governates around Jordan, in three types: (Pfizer, Sinopharm, and Astrazeneca). However, some populations weren’t vaccinated yet. Several factors maybe related to not practicing the vaccine by the population such as: knowledge, attitude, practice and accessibility of health care, particularly in areas with low socio-economic status. Therefore, studying factors affecting the approach towards vaccination is crucial to improve vaccination rates. Objective: To evaluate and assess the knowledge, attitude, and practices toward the COVID-19 vaccines in the Ghawr Al-safi population. Method: A cross sectional, population based study was conducted at Ghawr Al-safi. A random sample of 301 individuals was collected. A face to face interview of each participant was carried out by the reaseachers, using a well constructed, validated,and reliable questionnaire. The minimum(5,4, and4) and maximum(15,15,and 20) scores for the knowledge, attitude, and practice respectively. Results: Median age for the whole participants was 30, IQR=22.5-43.5 years. Females constitute 52.7%. of the participants .The most common sources of information about COVID-19 vaccines were television (68.7%) and social media (52.4%). Almost three quarters (74%) of the population were vaccinated with two doses, 61% were vaccinated with the Pfizer vaccine. The mean score for; Knowledge 7.75/15, attitude ,7.02/20. While for vaccine practice was relatively high with a mean of 14.62/20. The mean score on the satisfaction towards the healthcare services was 3.76/9. The practice scale was significantly correlated with the satisfaction (r= -0.299, p< 0.001),attitude (r= -0.387, p < 0.001), but not with knowledge (p = 0.448). The most prevalent reason (41%) for vaccination was to protect themselves and their families from COVID-19. What factors are related to practicing COVID-19 vaccine by population at Ghawr Al-Safi, Jordan Conclusion: Level of practice was significantly conversely correlated with attitude and not with knowledge. This indicates that people were vaccinated despite their doubts and apprehension toward the vaccines. Therefore, additional knowledge and awareness are required of Covid -19 and its consequences in that population. Keywords: covid-19, kap study , cross sectional
APA, Harvard, Vancouver, ISO, and other styles
8

Zhu, Richard, and Sujata Bhatia. "Optimizing COVID-19 Vaccine Diffusion in Respiratory Mucosa through Stokes-Einstein Modeling." In 2022 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2022. http://dx.doi.org/10.1115/dmd2022-1065.

Full text
Abstract:
Abstract SARS-COV-2 vaccines, all of which are currently intramuscular shots, have the ability to prevent serious injury. However, the absence of sufficient mucosal immunity is a major concern. To counteract this deficiency that has led to continued transmission from vaccinated individuals and breakthrough cases, reformulating vaccines to be inhalable presents a logical administration route. Predecessor research has reported the inhalable route to be viable as aerosolized vaccine nanoparticles, AAV phage nanoparticles, and PIV-5 viruses were recently identified to elicit immune responses. In this study, the diffusion of vaccine nanoparticles across the mucosa is characterized and modeled, with respect to their observed behavior from previous studies in relation to the Stokes-Einstein equation, to predict the most efficient model of an inhalable COVID-19 vaccine. The Stokes-Einstein equation has been used in several studies to predict diffusion coefficients. These predictions may be modified to fit the specifications of mucosal interactions. It was determined that mucosal interactions play a significant role in vaccine nanoparticle diffusion, as demonstrated by the viral vector and virus-like nanoparticle diffusion, and can be characterized by an equivalent hydrodynamic radius. Moreover, as a counter to mucosal interactions, PEGylation was found to drastically decrease the viscous slowing of the mucus medium.
APA, Harvard, Vancouver, ISO, and other styles
9

GIRARD, MARC. "CANCER VACCINES." In International Seminar on Nuclear War and Planetary Emergencies 38th Session. WORLD SCIENTIFIC, 2008. http://dx.doi.org/10.1142/9789812834645_0041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sun, Jianping. "Identifying Safety-Vaccine Association for COVID-19 Vaccines from VAERS." In 4th International Conference on Statistics: Theory and Applications (ICSTA'22). Avestia Publishing, 2022. http://dx.doi.org/10.11159/icsta22.148.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccines"

1

Ennis, Francis A., and Walter E. Demkowicz. Human Immune Responses to Experimental Vaccinia Vaccines. Fort Belvoir, VA: Defense Technical Information Center, July 1995. http://dx.doi.org/10.21236/ada299784.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Byrn, Stephen, Nathaniel Milton, and Kari Clase. BIRS Course: RNA Vaccine Manufacture and Assessment of Regulatory Documents for RNA Vaccines. Purdue University, August 2023. http://dx.doi.org/10.5703/1288284317657.

Full text
Abstract:
This paper is in three segments: (A) Segment on Vaccine Manufacture; (B) Segment on Ready to Use (RTU) Fluid Path for Compounded Sterile Preparations, mRNA Vaccines, and Phage Therapy, (C) Segment on Competency Framework for Addressing Regulatory Review These segments can be used separately or in combination. Additionally, they can be presented in any order. The time devoted to each segment depends on the depth of the course coverage. These segments are interrelated and describe how to make vaccines, how to manufacture vaccines with a point-of-care system built from ready-to-use parts; and how to regulate vaccines. This is a timely review because of the importance of vaccines for the treatment of diseases. It is hoped that it will lead to new approaches to vaccine manufacture and regulation.
APA, Harvard, Vancouver, ISO, and other styles
3

Gidengil, Courtney, Matthew Bidwell Goetz, Margaret Maglione, Sydne J. Newberry, Peggy Chen, Kelsey O’Hollaren, Nabeel Qureshi, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update. Agency for Healthcare Research and Quality (AHRQ), May 2021. http://dx.doi.org/10.23970/ahrqepccer244.

Full text
Abstract:
Objective. To conduct a systematic review of the literature on the safety of vaccines recommended for routine immunization in the United States, updating the 2014 Agency for Healthcare Research and Quality (AHRQ) report on the topic. Data sources. We searched MEDLINE®, Embase®, CINAHL®, Cochrane CENTRAL, Web of Science, and Scopus through November 9, 2020, building on the prior 2014 report; reviewed existing reviews, trial registries, and supplemental material submitted to AHRQ; and consulted with experts. Review methods. This report addressed three Key Questions (KQs) on the safety of vaccines currently in use in the United States and included in the Centers for Disease Control and Prevention’s (CDC) recommended immunization schedules for adults (KQ1), children and adolescents (KQ2), and pregnant women (KQ3). The systematic review was supported by a Technical Expert Panel that identified key adverse events of particular concern. Two reviewers independently screened publications; data were extracted by an experienced subject matter expert. Studies of vaccines that used a comparator and reported the presence or absence of adverse events were eligible. We documented observed rates and assessed the relative risks for key adverse events. We assessed the strength of evidence (SoE) across the existing findings from the prior 2014 report and the new evidence from this update. The systematic review is registered in PROSPERO (CRD42020180089). Results. A large body of evidence is available to evaluate adverse events following vaccination. Of 56,608 reviewed citations, 189 studies met inclusion criteria for this update, adding to data in the prior 2014 report, for a total of 338 included studies reported in 518 publications. Regarding vaccines recommended for adults (KQ1), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence in this update, including for newer vaccines such as recombinant influenza vaccine, adjuvanted inactivated influenza vaccine, and recombinant adjuvanted zoster vaccine. The prior 2014 report noted a signal for anaphylaxis for hepatitis B vaccines in adults with yeast allergy and for tetanus, diphtheria, and acellular pertussis vaccines. Regarding vaccines recommended for children and adolescents (KQ2), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence, including for newer vaccines such as 9-valent human papillomavirus vaccine and meningococcal B vaccine. The prior 2014 report noted signals for rare adverse events—such as anaphylaxis, idiopathic thrombocytopenic purpura, and febrile seizures—with some childhood vaccines. Regarding vaccines recommended for pregnant women (KQ3), we found no evidence of increased risk for key adverse events with varied SoE among either pregnant women or their infants following administration of tetanus, diphtheria, and acellular pertussis vaccines during pregnancy. Conclusion. Across this large body of research, we found no new evidence of increased risk since the prior 2014 report for key adverse events following administration of vaccines that are routinely recommended. Signals from the prior report remain unchanged for rare adverse events, which include anaphylaxis in adults and children, and febrile seizures and idiopathic thrombocytopenic purpura in children. There is no evidence of increased risk of adverse events for vaccines currently recommended in pregnant women. There remains insufficient evidence to draw conclusions about some rare potential adverse events.
APA, Harvard, Vancouver, ISO, and other styles
4

Korber, Bette T. M. Talk: Why Vaccines? Office of Scientific and Technical Information (OSTI), April 2014. http://dx.doi.org/10.2172/1129055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Roldan de Jong, Tamara. Rapid Review: Perceptions of COVID-19 Vaccines in South Africa. SSHAP, April 2022. http://dx.doi.org/10.19088/sshap.2021.021.

Full text
Abstract:
As of April 19, 2021, South Africa has recorded 1.56 million COVID-19 cases and almost 54,000 deaths - more than any other country on the African continent. The country has begun the national rollout of the Johnson & Johnson (J&J) COVID-19 vaccine, with over 292 thousand doses administered it aims to achieve herd immunity by vaccinating at least 67 percent of its population (around 40 million people) by the end of 2021. The government suspended its initial rollout of the AstraZeneca (AZ) vaccine due to concerns over its effectiveness, particularly against the new B.1.351 variant, which accounts for 90% of the infections in South Africa. The J&J vaccine was put on temporary hold in April due to concerns about rare clotting disorders. Although data show that expected acceptance of COVID-19 vaccines is relatively high, the suspension of two vaccines in South Africa, where fear of infection is decreasing, will likely influence public reactions. Understanding how individuals and population groups perceive and make sense of COVID-19 vaccines is critical to inform the design and implementation of risk communication and community engagement (RCCE) strategies, and guide interventions aiming to promote and sustain acceptance of COVID-19 vaccines, while encouraging compliance with other COVID-19 preventive measures. This review syntheses community perceptions of COVID-19 vaccines in South Africa to inform RCCE strategies and policies and provides examples of successful practice. It draws on multiple secondary data sources: scientific literature, qualitative and quantitative studies, grey literature, and mainstream and social media. The review was supported by consultation with four local expert key informants from different fields. It is part of the Social Science in Humanitarian Action Platform (SSHAP) series on social science considerations relating to COVID-19 vaccines. It was written for SSHAP by Tamara Roldan de Jong and Anthrologica on request of the UNICEF South Africa Country Office. Contributions were made from the RCCE Collective Service East and Southern Africa (ESAR) Region. The brief is the responsibility of SSHAP.
APA, Harvard, Vancouver, ISO, and other styles
6

Pilon, Shari. Recombinant Breast Cancer Vaccines. Fort Belvoir, VA: Defense Technical Information Center, September 1999. http://dx.doi.org/10.21236/ada384110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mitchell, Renae. Vaccines: Then and Now. Office of Scientific and Technical Information (OSTI), March 2022. http://dx.doi.org/10.2172/1859873.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Butler, Nadia, and Soha Karam. Evidence Review: COVID-19 Vaccine Acceptance by Key Influencers in the MENA Region - Teachers and Healthworkers. Institute of Development Studies (IDS), November 2021. http://dx.doi.org/10.19088/sshap.2021.039.

Full text
Abstract:
As COVID-19 vaccines have been deployed and scaled, concerns about vaccine acceptance have emerged. Effective management of the virus requires that communities everywhere buy into the public health measures designed to protect them, including vaccines. Low acceptance presents a serious challenge for achieving sufficient coverage to reduce circulation of the virus and the risk of new variants emerging. Surveys conducted early in the pandemic showed that the Middle East region had one of the lowest COVID-19 vaccine acceptance rates globally. The low acceptance is driven by specific factors in the region and its different countries and populations; these factors need to be taken into account when formulating policy, programmes and interventions. This review synthesises evidence on vaccine acceptance among two key groups in the Middle East and North Africa (MENA) region: teachers and health workers. It draws from academic studies most of which were cross-sectional studies, largely conducted between February 2020 and June 2021, and grey literature reports, including social listening reports. This review is intended to inform strategies for risk communications and community engagement (RCCE) relating to COVID-19 vaccine uptake, with the aim of boosting confidence in and acceptance of the vaccines among these groups across the region. It is part of the Social Science in Humanitarian Action Platform (SSHAP) series on social science considerations relating to COVID-19 vaccines and was developed for SSHAP by Anthrologica (Nadia Butler and Soha Karam) at the request of the UNICEF MENA Regional Office. It was reviewed by Rose Aynsley (WHO) Amaya Gillespie (UNICEF) and Olivia Tulloch (Anthrologica). The evidence review is the responsibility of SSHAP.
APA, Harvard, Vancouver, ISO, and other styles
9

Vallerani, Sara, Elizabeth Storer, and Costanza Torre. Key Considerations: Equitable Engagement to Promote COVID-19 Vaccine Uptake among Undocumented Urban Migrants. SSHAP, May 2022. http://dx.doi.org/10.19088/sshap.2022.013.

Full text
Abstract:
This brief sets out key considerations linked to the promotion of COVID-19 vaccine uptake among undocumented migrants residing in Rome, Italy. We focus on strategies to equitably distribute COVID-19 vaccines. Evidence from Italy is applicable to other contexts where vaccine administration is tied to “vaccine passports” or “immunity passes”. Undocumented migrants have been considered as some of the “hardest to reach” groups to engage in COVID-19 vaccination outreach. This brief uses the term undocumented migrant or migrant for brevity, but we refer to people living without formal Italian citizenship, refugee status or right to remain in Italy. This brief explores the everyday context of undocumented migrants lives, and how experiences of the COVID-19 pandemic have exacerbated difficult conditions. It links emerging vulnerabilities to perceptions of vaccines, and we suggest that migrants orientate themselves towards the vaccines within frameworks which prioritise economic survival. In many cases, migrants have accepted a COVID-19 vaccine to access paid employment, yet this has often generated mistrust in the state and healthcare system. Accordingly, this brief considers how vaccines can be distributed equitably to boost trust and inclusion in the post-pandemic world. This brief draws primarily on the ethnographic evidence collected through interviews and observations with undocumented migrants in Rome, along with civil society representatives and health workers between December 2021 and January 2022. This brief was developed for SSHAP by Sara Vallerani (Rome Tre University), Elizabeth Storer (LSE) and Costanza Torre (LSE). It was reviewed by Santiago Ripoll (IDS, University of Sussex), with further reviews by Paolo Ruspini (Roma Tre University) and Eloisa Franchi (Université Paris Saclay, Pavia University). The research was funded through the British Academy COVID-19 Recovery: G7 Fund (COVG7210058). Research was based at the Firoz Lalji Institute for Africa, London School of Economics. The brief is the responsibility of SSHAP.
APA, Harvard, Vancouver, ISO, and other styles
10

Tull, Kerina. Social Inclusion and Immunisation. Institute of Development Studies (IDS), February 2021. http://dx.doi.org/10.19088/k4d.2021.025.

Full text
Abstract:
The current COVID-19 epidemic is both a health and societal issue; therefore, groups historically excluded and marginalised in terms of healthcare will suffer if COVID-19 vaccines, tests, and treatments are to be delivered equitably. This rapid review is exploring the social and cultural challenges related to the roll-out, distribution, and access of COVID-19 vaccines, tests, and treatments. It highlights how these challenges impact certain marginalised groups. Case studies are taken from sub-Saharan Africa (the Democratic Republic of Congo, South Africa), with some focus on South East Asia (Indonesia, India) as they have different at-risk groups. Lessons on this issue can be learned from previous pandemics and vaccine roll-out in low- and mid-income countries (LMICs). Key points to highlight include successful COVID-19 vaccine roll-out will only be achieved by ensuring effective community engagement, building local vaccine acceptability and confidence, and overcoming cultural, socio-economic, and political barriers that lead to mistrust and hinder uptake of vaccines. However, the literature notes that a lot of lessons learned about roll-out involve communication - including that the government should under-promise what it can do and then over-deliver. Any campaign must aim to create trust, and involve local communities in planning processes.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccines' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography